Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JMUB | 48.80 | 0.18 | +0.37% |
| JPMorgan Municipal ETF (JMUB) | |||
| BSGR | 25.06 | 0.01 | +0.06% |
| Invesco BulletShares 2027 Treasury Bond ETF (BSGR) | |||
| FLUD | 24.94 | -0.01 | -0.04% |
| Franklin Ultra Short Bond ETF (FLUD) | |||
| KOCT | 36.04 | -0.66 | -1.79% |
| Innovator U.S. Small Cap Power Buffer ETF - October (KOCT) | |||
| GXRP | 17.13 | -1.49 | -8.00% |
| Grayscale XRP Trust ETF (GXRP) | |||
A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with AXSM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then AXSM could also see price increases.
| Ticker / NAME | Correlation To CYTK | 1D Price Change % | ||
|---|---|---|---|---|
| CYTK | 100% | -1.32% | ||
| AXSM - CYTK | 44% Loosely correlated | -4.66% | ||
| NAMS - CYTK | 42% Loosely correlated | -5.64% | ||
| ARQT - CYTK | 42% Loosely correlated | -2.98% | ||
| DARE - CYTK | 42% Loosely correlated | -9.91% | ||
| ROIV - CYTK | 40% Loosely correlated | -0.78% | ||
More | ||||
a company which engages in discovery and development of small molecule drug therapeutics
Industry Biotechnology
The Aroon Indicator for CYTK entered a downward trend on November 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 173 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 173 cases the stock moved lower. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 212 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-43.024) is normal, around the industry mean (3.596). P/E Ratio (-7.436) is within average values for comparable stocks, (-1.186). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.